Effect of hormone modulation therapy on bone tissue in the treatment of endometriosis

Cover Page


Cite item

Full Text

Abstract

This article presents a review of the current literature on the impact of such drugs as gonadotropin-releasing hormone agonists, aromatase inhibitors, and dienogest 2 mg, which are used for the treatment of external genital endometriosis, on the mineral density state. In the paper, we discuss the pathogenetic mechanisms of the effects of various bioactive compounds on bone and the results of domestic and foreign research.

About the authors

Maria A. Shalina

Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Author for correspondence.
Email: amarus@inbox.ru

MD, PhD, the Head of the Menopause and Women’s Health Center. The Department of Endocrinology of Reproduction

Russian Federation, Saint Petersburg

Maria I. Yarmolinskaya

Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: m.yarmolinskaya@gmail.com

MD, PhD, DSci (Medicine), Professor of the Russian Academy of Sciences, the Head of the Department of Endocrinology of Reproduction, the Head of the Diagnostics and Treatment of Endometriosis Center

Russian Federation, Saint Petersburg

Elena V. Misharina

Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: mishellena@gmail.com

MD, PhD, Senior Researcher. The Department of Endocrinology of Reproduction

Russian Federation, Saint Petersburg

References

  1. Ярмолинская М.И., Айламазян Э.К. Генитальный эндометриоз. Различные грани проблемы. - СПб.: Эко-Вектор, 2017. [Yarmolinskaya MI, Aylamazyan EK. Genital’nyy endometrioz. Razlichnye grani problemy. Saint Petersburg: Eko-Vektor; 2017. (In Russ.)]
  2. Ярмолинская М.И., Денисова В.М. Современные подходы к назначению add-back-терапии больным генитальным эндометриозом // Эффективная фармакотерапия. - 2015. - № 4. - C. 24-31. [Yarmolinskaya MI, Denisova VM. Modern Approaches to Add-Back Therapy in Patients with Genital Endometriosis. Effektivnaya farmakoterapiya. 2015;(4):24-31. (In Russ.)]
  3. Sakamoto S, Sassa S, Mitamura T, et al. Prevention of Osteopenia Induced with a Gonadotropin-Releasing Hormone Agonist in Rats. Calcif Tissue Int. 1999;65(2):152-155. doi: 10.1007/s002239900675.
  4. Kaya A, Cayir A, Turan MI, Ozkan B. An Examination of the Effects of Leuprolide Acetate Used in the Treatment of Central Precocious Puberty on Bone Mineral Density and 25-Hydroxy Vitamin D. West Indian Med J. 2015;64(2):104-107. doi: 10.7727/wimj.2014.346.
  5. Молотков А.С. Эффективность применения ингибитора ароматазы в комбинированном лечении наружного генитального эндометриоза: Автореф. дис. … канд. мед. наук. - СПб., 2013. [Molotkov AS. Effektivnost’ primeneniya ingibitora aromatazy v kombinirovannom lechenii naruzhnogo genital’nogo endometrioza. [dissertation] Saint Petersburg; 2013. (In Russ.)]
  6. Imai A, Matsunami K, Ichigo S, Takagi H. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study. Gynecol Endocrinol. 2016;32(3):250-252. doi: 10.3109/09513590.2015.1112783.
  7. Soliman AM, Bonafede M, Farr AM, et al. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy. J Manag Care Spec Pharm. 2016;22(5):573-587. doi: 10.18553/jmcp.2016.22.5.573.
  8. Cho YH, Um MJ, Kim SJ, et al. Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density. J Menopausal Med. 2016;22(3):174-179. doi: 10.6118/jmm.2016.22.3.174.
  9. Khachidze N, Giorgadze E, Tsagareli M. Adjuvant (Hormonal) Therapy as a Cause of Bone Loss in Patients with Breast Cancer (Review of Literature). Georgian Med News. 2017(262):39-42.
  10. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24(22):3629-3635. doi: 10.1200/JCO.2005.05.4882.
  11. Zaman K, Thurlimann B, Huober J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol. 2012;23(6):1474-1481. doi: 10.1093/annonc/mdr448.
  12. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21(8):1215-1223. doi: 10.1359/jbmr.060508.
  13. Goss PE, Hershman DL, Cheung AM, et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol. 2014;15(4):474-482. doi: 10.1016/s1470-2045(14)70035-x.
  14. Lopez LM, Grimes DA, Schulz KF, et al. Steroidal contraceptives: effect on bone fractures in women. Cochrane DatabaseSyst Rev. 2014. doi: 10.1002/14651858.CD006033.pub5.
  15. Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121(3):593-600. doi: 10.1097/AOG.0b013e318283d1a1.
  16. Seo JW, Lee DY, Yoon BK, Choi D. Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density. Eur J Obstet Gynecol Reprod Biol. 2017;212:9-12. doi: 10.1016/j.ejogrb.2017.03.011.
  17. Балан В.Е., Орлова С.А., Кузнецов С.Ю., и др. Влияние лечения эндометриоза диеногестом в течение года на минеральную плотность костной ткани // Проблемы репродукции. - 2017. - Т. 23. - № 6. - С. 66-70. [Balan VE, Orlova SA, Kuznetsov SY, et al. Effects of dienogest on bone mineral density during the year of endometriosis treatment. Modern reproductive technologies. 2017;23(6):66-70. (In Russ.)]. doi: 10.17116/repro201723666-70.
  18. Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633-641. doi: 10.1093/humrep/dep469.
  19. Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis - a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675-681. doi: 10.1016/j.fertnstert.2007.12.080.

Copyright (c) 2018 Shalina M.A., Yarmolinskaya M.I., Misharina E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies